What changed today in Metabolic: 13 trial updates, 2 new studies
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records13 sources1 min read
Tirzepatide
Tirzepatide is a dual GIP and GLP-1 receptor agonist developed by Eli Lilly and marketed as Mounjaro and Zepbound for different indications.
High attention
- Editorial attention
- High attention
- Tracked this week
- 11
- Sources this week
- 4
- Last activity
- 4 days ago
Signal strength reflects editorial attention across tracked sources — not medical certainty or strength of evidence.
- Pending editorial review
A system check is an automated check of the official sources, not a human review. An editorial review is recorded only when one of our editors has reviewed the page.
Tirzepatide at a glance
- About this topic
- Tirzepatide is a dual GIP and GLP-1 receptor agonist developed by Eli Lilly and marketed as Mounjaro and Zepbound for different indications.
- Current status
- No editor-reviewed status summary yet. The official records below update automatically.
- Last updated
- Primary sources
- Latest official record: Trial status changed to “Recruiting”: TOPAZ (Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial) (opens the source in a new tab) (ClinicalTrials.gov (U.S. National Library of Medicine), Nov 11, 2026)
- Key facts from tracked records
- 88 clinical trials tracked from ClinicalTrials.gov
- 20 NPHLA briefings on this topic
What’s the latest on Tirzepatide?
20 totalWhat changed today in Metabolic: 5 trial updates, 1 new study
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records9 sources1 min read
What changed today in Metabolic: 5 trial updates, 3 new studies
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records11 sources1 min read
What changed today in Metabolic: 2 trial updates
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records4 sources1 min read
What changed today in Metabolic: 2 new studies
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records3 sources1 min read
What changed today in Metabolic: 3 trial updates, 1 new study
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records4 sources1 min read
What changed today in Metabolic: 6 trial updates
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records9 sources1 min read
What changed today in Regulatory: 1 recall record
Every new official record on the Pharmacy, Compounding & Regulatory Intelligence desk since this morning, each linked to its primary source.
Automated from official records2 sources1 min read
What do the official records show?
Primary sources and peer-reviewed research- Trial status changed to “Recruiting”: TOPAZ (Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial) (opens the source in a new tab)
Phase 2/Phase 3, yifang zhu. Previously “Not yet recruiting”. Conditions: Acute Ischemic Stroke (AIS). Interventions: Tirzepatide; Standard Medical Care (SMC). Investigational: trial-stage therapies are not approved for the use studied.
- New trial registered: RESIST-EXHALE (Breath Acetone During Tirzepatide Treatment and Resistance Training in Adults With Obesity) (opens the source in a new tab)
Technical University of Munich. Conditions: Obesity (Disorder). Interventions: Structured resistance training; Tirzepatide. Investigational: trial-stage therapies are not approved for the use studied.
- Results posted on ClinicalTrials.gov: SURPASS-EARLY (A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes) (opens the source in a new tab)
Phase 4, Eli Lilly and Company. Conditions: Type 2 Diabetes. Interventions: Tirzepatide; Antihyperglycemic medication. Investigational: trial-stage therapies are not approved for the use studied.
- New trial registered: RESIST-EXPLORE (Molecular and Microbiome Changes During Tirzepatide Treatment and Resistance Training in Obesity) (opens the source in a new tab)
Technical University of Munich. Conditions: Obesity (BMI Equal to or >30). Interventions: Structured resistance training; Tirzepatide. Investigational: trial-stage therapies are not approved for the use studied.
- New trial registered: RESIST-MIND (Functional, Cognitive, and Behavioral Correlates of Resistance Training During Tirzepatide-Induced Weight Loss) (opens the source in a new tab)
Technical University of Munich. Conditions: Obesity (Disorder). Interventions: Structured resistance training; Tirzepatide. Investigational: trial-stage therapies are not approved for the use studied.
- Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial (opens the source in a new tab)
- New trial registered: Ocular Changes in Patients Using Tirzepatide or Semaglutide (opens the source in a new tab)
Istanbul University. Conditions: Type 2 Diabetes Mellitus; Obesity. Interventions: Semaglutide; Tirzepatide. Investigational: trial-stage therapies are not approved for the use studied.
- Trial status changed to “Recruiting”: AMPLIFY-2 (A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes) (opens the source in a new tab)
Phase 3, Eli Lilly and Company. Previously “Not yet recruiting”. Conditions: Obesity; Overweight; Diabetes Mellitus, Type 2. Interventions: eloralintide and tirzepatide; Tirzepatide. Investigational: trial-stage therapies are not approved for the use studied.
Which clinical trials are being tracked?
All trials- GLP-1 Receptor Agonists in the Surgical Patient: Prevalence, Epidemiology, and Pulmonary Complications
University of Virginia. Conditions: GLP-1 Receptor Agonist Treatment. Investigational — not approved for the use studied.
- SURMOUNT-1: Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)
Hudson Biotech. Conditions: Obesity; Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities. Investigational — not approved for the use studied.
- RESIST-EXHALE: Breath Acetone During Tirzepatide Treatment and Resistance Training in Adults With Obesity
Technical University of Munich. Conditions: Obesity (Disorder). Investigational — not approved for the use studied.
- SURPASS-EARLY: A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes
Eli Lilly and Company. Conditions: Type 2 Diabetes. Results posted 2026-11-12. Investigational — not approved for the use studied.
- RESIST-EXPLORE: Molecular and Microbiome Changes During Tirzepatide Treatment and Resistance Training in Obesity
Technical University of Munich. Conditions: Obesity (BMI Equal to or >30). Investigational — not approved for the use studied.
- A Study to Evaluate ALN-2232 in Participants With Obesity
Alnylam Pharmaceuticals. Conditions: Obesity. Investigational — not approved for the use studied.
Industry coverage
Headlines link to the original publication- STAT+: Former Eli Lilly rep claims she was fired for complaining about marketing of Mounjaro diabetes drug (opens the source in a new tab)
- Lilly–Hims & Hers GLP-1 Deal Tests Whether Convenience Can Deliver Continuity of Care (opens the source in a new tab)
- FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk (opens the source in a new tab)
- STAT+: Eli Lilly’s GLP-1 pill Foundayo helped alleviate sleep apnea in studies (opens the source in a new tab)